April 9, 2021 -- InvestorsHub NewsWire -- via BullishInvestor.com/PAOG
The stock price direction for the day for PAOG is UP. The stock is
experiencing a strong uptrend as of late, with an increase of more
than 15 percent in the last five days.
From the Digital
Journal on PAOG
PAO Group, Inc. Has Two CBD-Based Therapeutics In Play; Planned
Launch For One In September Puts Catalyst In Play
PAO Group, Inc. (USOTC: PAOG)
stock is likely to build positive momentum ahead of plans to launch
its first CBD-based nutraceutical product next quarter. In a
release last month, PAOG said it has supplemented its RespRx COPD
program, adding CBD RELAX-RX, a nutraceutical targeting the
treatment for anxiety and depression. That market is expected to
reach a value of $18 billion by 2025 and puts a second
billion-dollar market opportunity in play.
The September 2021 "go-to-market" would be a sure catalyst for
PAOG. And helping that cause is Alkame Holdings, Inc. (OTC
Pink: ALKM) and North American Cannabis Holdings, Inc.
(OTC
Pink: USMJ), slated to provide logistical and marketing
expertise. Combined, the three should have the firepower needed to
bring this potentially lucrative revenue-generating asset to
market.
Further, the run toward commercialization could put the stock
back into rally mode and send shares back toward highs of $0.02 set
in February. From current levels, that translates into a more than
177% gain. And that increase could stem from news of just a single
product launch. PAOG has other promising products in the queue as
well.
PAOG Could Rally Ahead Of Planned September
Launch
Investors should note that PAOG is developing a comprehensive
CBD nutraceuticals program that could deliver substantial long-term
rewards despite its sub-penny price. In fact, its investment and
research in developing targeted CBD-based pharmaceutical and
nutraceuticals products positions PAOG for both near and long-term
gains. Better still, with the company already expecting to post
revenue this year, commercialization of either CBD RALAX-RX or
RespRx later this year would compound revenue growth and help to
crush current revenue estimates. That would be great news for the
company and its investors.
The transformation at PAOG began after it acquired RespRx from
Kali-Extracts, Inc. (OTC Pink: KALY). That asset is a patented
development-stage CBD-based treatment for Chronic Obstructive
Pulmonary Disorder (COPD). The patent, by the way, is a crucial
asset that protects methodology to extract potent CBD properties
derived from cannabis. That market protection could be valuable on
several business fronts.
In fact, it not only protects PAOG's investments in research but
also positions them to benefit from licensing and partnership
opportunities. And those could come ahead of its planned CBD
nutraceutical products launch in Q3. There, two treatments are in
play.
Video Link: https://www.youtube.com/embed/mlG8HDv06uk
CBD-Based Therapeutics Targeting Massive
Markets
Its first, RespRx, is a CBD nutraceutical product targeting the
Chronic Obstructive Pulmonary Disorder (COPD) market. That
debilitating disease affects more than 60 million people and has an
addressable treatment market that surpassed $10 billion in 2016.
It's listed as the third leading cause of death worldwide, with the
market expected to surge to a $14.1 billion treatment opportunity
by 2025.
Helping to expedite its development and planned approvals, PAOG
is working directly with the Puerto Rico Consortium for Clinical
Investigation (PRCCI). The good news is that the relationship could
extend to additional research partnerships and accelerate the
development of other CBD-based initiatives.
In fact, the existing relationship could benefit the development
of CBD RELAX-RX in that market. As noted, that nutraceutical
targets a billion-dollar anxiety and depression market opportunity
that is expected to reach $18 billion in size by 2025. Importantly,
don't let PAOG's market cap fool you. Although they are a small
company, with assets and patents in hand, they are well-positioned
to earn a share of a lucrative opportunity.
Moreover, with CBD showing itself to be a safer alternative to
prescribed pharmaceuticals, PAOG could be as well-positioned as any
to capitalize on opportunities in these two markets.
Having revenues helps.
Revenue Is A Defining Advantage For
PAOG
Keep in mind, PAOG has a unique advantage over most of its
nano-cap peers- they are generating revenues. That, in and of
itself, is worthy of higher valuations. Earlier this year, PAOG
said it expects to generate $300,000 in sales from its cannabis
cultivation subsidiary. Although not a lot by large-cap standards,
for PAOG, it could be enough to bring its products to market and
increase R&D efforts to target other CBD-based therapeutics and
nutraceutical market opportunities.
For now, though, PAOG has as good a chance as any to maximize
its assets. In fact, given time, there is reason to believe they
can earn a similar growth trajectory to that of GW Pharma
(NASDAQ: GWPH). That
company took years to develop a product, had massive swings in
share price, and endured years of shareholder scrutiny. But they
pioneered a sector that opens the door to even the smallest of
companies.
Thus, with CBD-based therapeutics now widely accepted as
effective treatments and sold across the country, PAOG could very
well exceed expectations, especially with partnerships and/or
licensing agreements to provide development capital. Still, PAOG
expects to market its first product on its own by September,
putting a near-term catalyst in play, regardless of whether it inks
a deal.
That could make the next two quarters an exciting time to be a
PAOG shareholder. And if they can successfully bring RespRx and/or
CBD RELAX-RX to market as planned, the rewards can be
substantial.
Precedent Of Value In CBD-Based
Therapeutics
Look no further than the deal that Jazz Pharma
(NASDAQ: JAZZ) made
to acquire GW Pharma. They purchased that company for $7.2 billion
earlier this year and caused a rush for investors to find emerging
players in the sector. It was at that same time that PAOG saw a
massive surge in value. And, with investors rotating back toward
the CBD sector, PAOG could again be in focus.
Better still, its two drugs in development and a patented
extraction process in hand could produce the initial wave of
interest. Additional value can be earned when investors affirm the
company as a viable products-based contender in its respected
markets.
Thus, despite its roughly 260% year-to-date gains, PAOG could
have substantial room to run higher. That is especially true if its
first planned product launch stays on schedule for next quarter.
Certainly, PAOG would be ideally positioned to create shareholder
value from partnerships and/or licensing agreements if it does. In
fact, either type of agreement could initiate a formidable
development campaign that leverages its patents, secures its
competitive advantage, and maximizes its opportunities in at least
two billion-dollar treatment markets.
All of the scenarios above bode well for PAO Group, Inc. They
also make this nano-cap CBD therapeutics company well-positioned
for exponential growth in 2021. In short, keep PAOG in focus.
Disclaimers: Hawk Point Media is responsible for the
production and distribution of this content. Hawk Point Media is
not operated by a licensed broker, a dealer, or a registered
investment adviser. It should be expressly understood that under no
circumstances does any information published herein represent a
recommendation to buy or sell a security. Our
reports/releases are a commercial advertisement and are for general
information purposes ONLY. We are engaged in the business of
marketing and advertising companies for monetary compensation.
Never invest in any stock featured on our site or emails unless you
can afford to lose your entire investment. The
information made available by Hawk Point Media is not intended to
be, nor does it constitute, investment advice or recommendations.
The contributors may buy and sell securities before and after any
particular article, report and publication. In no event shall Hawk
Point Media be liable to any member, guest or third party for any
damages of any kind arising out of the use of any content or other
material published or made available by Hawk Point Media,
including, without limitation, any investment losses, lost profits,
lost opportunity, special, incidental, indirect, consequential or
punitive damages. Hawk Point Media was compensated
three-thousand-five-hundred-dollars by wire transfer to produce
research, video, email, newsletters, and editorial commentary for
PAO Holdings Group, Inc.. by a third party. Past performance is a
poor indicator of future performance. The information in this
video, article, and in its related newsletters, is not intended to
be, nor does it constitute, investment advice or recommendations.
Hawk Point Media strongly urges you conduct a
complete and independent investigation of the respective companies
and consideration of all pertinent risks. Readers are advised to
review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider
reports, Forms 3, 4, 5 Schedule 13D.
The Private Securities Litigation Reform Act of 1995
provides investors a safe harbor in regard to forward-looking
statements. Any statements that express or involve discussions with
respect to predictions, expectations, beliefs, plans, projections,
objectives, goals, assumptions or future events or performance are
not statements of historical fact may be forward looking
statements. Forward looking statements are based on expectations,
estimates, and projections at the time the statements are made that
involve a number of risks and uncertainties which could cause
actual results or events to differ materially from those presently
anticipated. Forward looking statements in this action may be
identified through use of words such as projects, foresee, expects,
will, anticipates, estimates, believes, understands, or that by
statements indicating certain actions & quote; may, could, or
might occur. Understand there is no guarantee past performance will
be indicative of future results.Investing in
micro-cap and growth securities is highly speculative and carries
an extremely high degree of risk. It is possible that an investors
investment may be lost or impaired due to the speculative nature of
the companies profiled.
Media Contact
Company Name: Hawk Point Media
Contact Person: KL Feigeles
Email: Send
Email
City: Miami Beach
State: Florida
Country: United States
Website: https://www.greenlightstocks.com
Read more: http://www.digitaljournal.com/pr/5028661#ixzz6rXgqqBze
Other stocks on the move include
RGBPP, FTEG and eEENF
SOURCE: BullishInvestor.com/PAOG
Regen Biopharma (PK) (USOTC:RGBPP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Regen Biopharma (PK) (USOTC:RGBPP)
Historical Stock Chart
From Sep 2023 to Sep 2024